medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

1999, Number 5

Next >>

Alerg Asma Inmunol Pediatr 1999; 8 (5)

Therapeutic effects of Accolate® in a moderate and severe asthmatic group after 12 weeks of treatment

Abdo RA, Dobarganes SY, Martínez PR

Language: Spanish
References: 21
Page: 126-130
PDF size: 287.03 Kb.


ABSTRACT

The results are presented obtained by the employment of 12 weeks of Zafirlukast, an leukotrien receptor antagonist in asthmatic patients bigger than 12 years of age. Clinical improvement existed in 80.3% of the patients. Likewise 85.3% had improvement in its respiratory function. Tha patients had reduction in the employment of oral steroids and only 2 adverse reactions were reported.


REFERENCES

  1. Brocklehurst WE. The release of histamine and formation of a slow reacting substance (SRS-A) during anaphylactic shock. J Physiol 1960; 151: 416-35.

  2. Orange RP, Austen KF. Slow reacting substance of anaphylaxis. Adv Immunol 1969; 10: 105-44.

  3. «Global initiative for asthma» NHLBI/WHO. Workshop report, 1995.

  4. Gadde JN, Busse WW, Sheffer AL. Fatal Asthma. In: Weiss EB, Stein M, eds. Bronchial Asthma: Mechanism and therapeutics 3rd ed. Boston: Little Brown, 1993; 1154-1166.

  5. Weiss KB, Wagener DK. Changing pattern of Asthma mortality: identifying target populations at high risk. Jama 1990; 264: 1683-1687.

  6. Sly RM. Mortality from Asthma, 1979-1984 J Allergy Clin Immunol 1988; 82: 705-717.

  7. Feldberg W, Kellaway CH. Liberation of histamine and formation of lecithin-like substance by cobra venom. J of Physiolog 1938; 94: 187-226.

  8. Chung KF. Leukotriene receptor antagonists and biosynthesis inhibitors. Potential breakthrough in asthma therapy. Eu Respir J 1995; 8: 1203-1213.

  9. Adelroth E et al. Airway, responsiveness to leukotriene C4 and D4 and to metacholine in patients with asthma and normal controls. N Eng J Med 1986; 315: 480-484.

  10. Barnes NC, Piper PJ, Costello JF. Comparative effects of inhaled leukotriene C4 and leukotriene D4 and histamine in normal human subjects Thorax 1984; 49: 500-504.

  11. Piacentini GL, Kaliner MA. The potential roles of leukotrienes in bronchial asthma. Am Rev Resp Dis 1991; 143: 96-99.

  12. Marom Z et al. Slow reacting substances, leukotriene C4 and D4, increases the release of mucus from human airways in vitro. Am Rev Respir Dis 1982; 126: 449-451.

  13. Dahlen SE et al. Allergen challenge of lung tissue from asthmatics elicits bronchial contraction that correlate with the release of leukotrienes C4, D4 and E4. Proc Natl Acad Sci USA 1983; 80: 1772-1716.

  14. New Strategies in the medical management of asthma. 1998 American Academy of Allergy and Clinical Immunology. 8-9.

  15. Kikawa Y et al. Urinary leukotrienes E4 after exercise challenge in children with asthma. J allergy Clin Immunol 1992; 89: 1111-1119.

  16. Sampson AP, Castling DP, Green CP, Price JF. Persistent increase in plasma and urinary leukotrienes after acute asthma. Arch Dis Child 1995; 73: 221-225.

  17. Israel E et al. The effects of a 5-lipoxygenase inhibitors in asthma induced by cold, dry air. N Eng J Med 1990; 323: 1740-1744.

  18. Friedman BS et al. Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am Rev Respir Dis 1993; 147: 839-844.

  19. Baldinger SL, Shore ET. Focus on Zafirlukast: Leukotriene receptor antagonist for the prophylaxis and chronic treatment of Asthma. Formulary 1996; 31: 1029-1052.

  20. Owens CA, Grundy GW. Focus on Zileuton: First FDA-approved agent of a new class of drugs - 5 - lipoxygenase inhibitors the management of Asthma. Formulary 1997; 32: 455-471.

  21. Lockey RF et al. J Allergy Clin Immunol 1995; 95(1, part2); Abs. 839 (AN 34361).




2020     |     www.medigraphic.com